STANDARD THERAPY WITH NICORANDIL AND ISOSORBIDE DINITRATE FOR CORONARY HEART DISEASE AND ITS CONCURRENCE

Download full text PDF
Issue: 
2
Year: 
2017

Yu. Solodova; Professor A. Adamchik, MD; I. Kryuchkova, Candidate of Medical Sciences Kuban State Medical University, Krasnodar

The study has solved the following tasks: to optimize pharmacotherapy in patients with stable angina and to compare the efficiency of standard therapy for coronary heart disease (CHD) with bisoprolol, valsartan, aspirin, and rosuvastatin and its concurrence with isosorbide dinitrate and nicorandil. Standard therapy for CHD is highly effective in treating patients with stable angina and the addition of nicorandil provides more pronounced and significant anti-anginal, endothelioprotective, and anti-atherosclerotic effects.
Keywords: 
cardiology
coronary heart disease
exertional angina
isosorbide dinitrate
nicorandil
anti-anginal and anti-atherosclerotic efficacy
obesity

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Roger V., Go A., Lloyd-Jones D. et al. Heart disease and stroke statistics—2012 update a report from the American heart association // Circulation. – 2012; 125 (1): 2–220.
  2. Ferrari R. et al. Geographic variations in prevalence and management of cardiovascular risk factors in 33 283 outpatients with CAD: data from the contemporary CLARIFY registry from 45 countries // Eur. Heart J. – 2013; 34 (Suppl. 1): 2777.
  3. Bubnova M.G. i dr. Klinicheskaja harakteristika i obschie podhody k lecheniju patsientov so stabil'noj stenokardiej v real'noj praktike //Rossijskoe issledovanie PERSPEKTIVA (ch. I) // Kardiovask. ter. i profilakt. – 2010; 6: 47–56.
  4. Shal'nova S.A. i dr. Ishemicheskaja bolezn' serdtsa. Sovremennaja real'nost' po dannym vsemirnogo registra CLARIFY // Kardiologija. – 2013; 53 (8): 28–33.
  5. /WHO/Europe, European mortality database (MDB), Jan 2013. http://data.euro.who.int/hfadb
  6. World Health Organization et al. The European health report 2012: charting the way to well-being / Copenhagen: World Health Organization Regional Office for Europe, 2013.
  7. Montalescot G., Sechtem U., Achenbach S., et al. 2013 ESC guidelines on the management of stable coronary artery disease // Eur. Heart J. – 2013; 34 (38): 2949–3003.
  8. Wagner G. Selected issues from an overview on nicorandil: tolerance, duration of action, and long-term efficacy // J. Cardiovasc. Pharmacol. – 1992; 20 (Suppl. 3): S86–92.
  9. Gori T., Parker J. Nitrate-induced toxicity and preconditioning: a rationale for reconsidering the use of these drugs // J. Am. Coll. Cardiol. – 2008; 52: 251–4.
  10. Dunn N., Freemantle S., Pearce G. et al. Safety profile of nicorandil–prescription-event monitoring (PEM) study // Pharmacoepidemiol. Drug Saf. – 1999; 8: 197–205.
  11. Rezvanova (Solodova) Ju.A., Adamchik A.S. Otsenka antiishemicheskoj i kardioprotektivnoj effektivnosti nikorandila u patsientov so stabil'noj stenokardiej // Kardiologija. – 2015; 55 (8): 21–5.
  12. Witchitz S., Darmon J. Nicorandil safety in the long-term treatment of coronary heart disease // Cardiovasc. Drugs Ther. – 1995; 9 (Suppl. 2): 237–43.
  13. Martsevich S.Ju., Kutishenko N.P., Deev A.D., ot imeni uchastnikov issledovanija «KVAZAR». Izuchenie vlijanija nikorandila na kachestvo zhizni patsientov so stabil'noj stenokardiej v ramkah issledovanija «KVAZAR» // Ratsional'naja farmakoterapija v kardiologii. – 2016; 12 (6):654–60. DOI:http://dx.doi.org/10.20996/1819-6446-2016-12-6-654-660.
  14. Rjabihin E.A., Mozhejko M.E., Krasil'nikova Ju.A. Otsenka vlijanija terapii nikorandilom na pokazateli kachestva zhizni i prognoza u bol'nyh stabil'noj stenokardiej // Kardiologija. – 2016; 11: 12–7.
  15. Sizova Zh.M., Zaharova V.L., Kozlova N.V. i dr. Vlijanie aktivatora kalievyh kanalov nikorandila na kachestvo zhizni bol'nyh ishemicheskoj bolezn'ju serdtsa so stabil'noj stenokardiej naprjazhenija // Kardiologija. – 2016; 6 (6): 26–31.
  16. IONA Study Group et al. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial // Lancet. – 2002; 359 (9314): 1269–75.
  17. Bulahova E. Ju., Korennova O. Ju., Kondrasheva M. N. i dr. Klinicheskie preimuschestva terapii nikorandilom v sravnenii s izosorbid-5-mononitratom u bol'nyh IBS // Serdtse. – 2013; 12 (2): 83–7.
  18. Thomas G., DiFabio J., Gori T. et al. Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism // J. Am. Coll. Cardiol. – 2007; 49: 1289–95.
  19. Kjekshus J., Apetrei E., Barrios V. et al. Rosuvastatin in older patients with systolic heart failure // N. Engl. J. Med. – 2007; 357 (22): 2248–61.